Psychedelic Therapy: A Primer for Primary Care Clinicians-5-Methoxy-N,N-Dimethyltryptamine.

Abstract

<h4>Background</h4>5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), also officially known as mebufotenin, is a naturally occurring serotonergic psychedelic alkaloid found in the venom of the Sonoran Desert toad ( Incilius alvarius ) and various plant species.<h4>Areas of uncertainty</h4>Trace levels of 5-MeO-DMT may be produced endogenously in humans, but its physiologic role remains unclear. Safety profiles indicate low risk in controlled settings, though longer-term follow-ups with human subjects may be needed. Phenomenological overlaps with near-death experiences are noted but debated.<h4>Therapeutic advances</h4>Clinical trials have demonstrated rapid antidepressant effects. Top-line data from a recent phase 2b trial showed that 57.5% of participants remitted from treatment-resistant depression within 8 days. Other phase 2a and 2b trials have provided further, though still preliminary, evidence that 5-MeO-DMT may reduce depressive symptoms more than existing pharmacologic treatments, like selective serotonin reuptake inhibitors.<h4>Limitations</h4>Most studies are early phase with small samples (n ≤193). Only 2 double-blind randomized controlled trials (RCTs) have been conducted in clinical populations, and long-term effects require further investigation.<h4>Conclusions</h4>Emerging evidence supports 5-MeO-DMT as a promising, ultra-short-acting psychedelic for treatment-resistant depression and other psychiatric conditions, warranting larger RCTs.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

Keywords